Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study

被引：24
|
作者：
Matulonis, Ursula A.
Shapira-Frommer, Ronnie
Santin, Alessandro
Lisyanskaya, Alla Sergeevua
Pignata, Sandro
Vergote, Ignace
Raspagliesi, Francesco
Sonke, Gabe S.
Birrer, Michael
Provencher, Diane M.
Sehouli, Jalid
Colombo, Nicoletta
Gonzalez-Martin, Antonio
Oaknin, Ana
Ottevanger, P. B.
Rudaitis, Vilius
Katchar, Kia
Wang, Zhen
Ruman, Jane
Ledermann, Jonathan A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Sheba Med Ctr, Ramat Gan, Israel
[3] Yale Univ, Sch Med, New Haven, CT USA
[4] St Petersburg City Oncol Hosp, St Petersburg, Russia
[5] NCI Naples, Naples, Italy
[6] Univ Hosp Leuven, Leuven, Belgium
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Netherlands Canc Inst, Amsterdam, Netherlands
[9] BOOG Study Ctr, Amsterdam, Netherlands
[10] Univ Alabama Birmingham, Birmingham, AL USA
[11] Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada
[12] Charite Med Univ Berlin, Berlin, Germany
[13] Univ Milano Bicocca, Milan, Italy
[14] European Inst Oncol, Milan, Italy
[15] Clin Univ Navarra, MD Anderson Int Espana, Madrid, Spain
[16] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[17] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[18] Vilnius Univ, Inst Clin Med, Vilnius, Lithuania
[19] Merck Co Inc, Kenilworth, NJ USA
[20] UCL, Canc Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5511
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study
    Hsu, C.
    Lee, S. -H.
    Ejadi, S.
    Even, C.
    Cohen, R.
    Le Tourneau, C.
    Mehnert, J.
    Algazi, A.
    van Brummelen, E.
    Saraf, S.
    Thanigaimani, P.
    Cheng, J.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 94 - 94
  • [22] Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: Interim results
    Yin, Chao
    Armstrong, Samantha Ann
    Agarwal, Seema
    Wang, Hongkun
    Noel, Marcus Smith
    Weinberg, Benjamin Adam
    Marshall, John
    He, Aiwu Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open- label, multicenter phase 2 basket study
    Xia, Lingfang
    Peng, Jin
    Lou, Ge
    Pan, Mei
    Zhou, Qi
    Hu, Wenjing
    Shi, Huirong
    Wang, Li
    Gao, Yunong
    Zhu, Jianqing
    Zhang, Yu
    Sun, Rong
    Zhou, Xianfeng
    Wang, Quanren
    Wu, Xiaohua
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [24] Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.
    Frenel, Jean-Sebastien
    Le Tourneau, Christophe
    O'Neil, Bert H.
    Ott, Patrick Alexander
    Piha-Paul, Sarina Anne
    Gomez-Roca, Carlos Alberto
    Van Brummelen, Emilie
    Rugo, Hope S.
    Thomas, Shari
    Saraf, Sanatan
    Chen, Mei
    Varga, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164
    Le, D.
    Kavan, P.
    Kim, T.
    Burge, M.
    Van Cutsem, E.
    Hara, H.
    Boland, P.
    Van Laethem, J.
    Geva, R.
    Taniguchi, H.
    Crocenzi, T.
    Sharma, M.
    Atreya, C.
    Diaz, L.
    Liang, L.
    Marinello, P.
    Dai, T.
    O'Neill, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
    Piha-Paul, Sarina A.
    Oh, Do-Youn
    Ueno, Makoto
    Malka, David
    Chung, Hyun Cheol
    Nagrial, Adnan
    Kelley, Robin K.
    Ros, Willeke
    Italiano, Antoine
    Nakagawa, Kazuhiko
    Rugo, Hope S.
    de Braud, Filippo
    Varga, Andrea Iolanda
    Hansen, Aaron
    Wang, Hui
    Krishnan, Suba
    Norwood, Kevin G.
    Doi, Toshihiko
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (08) : 2190 - 2198
  • [27] Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort
    Seiwert, Tanguy Y.
    Haddad, Robert I.
    Gupta, Shilpa
    Mehra, Ranee
    Tahara, Makoto
    Berger, Raanan
    Lee, Se-Hoon
    Burtness, Barbara
    Le, Dung T.
    Heath, Karl
    Blum, Amy
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Pathiraja, Kumudu
    Cheng, Jonathan D.
    Chow, Laura Q.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [28] Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study
    Schellens, Jan H. M.
    Marabelle, Aurelien
    Zeigenfuss, Susan
    Ding, Jie
    Pruitt, Scott Knowles
    Chung, Hyun Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
    Modi, Shanu
    Park, Haeseong
    Murthy, Rashmi K.
    Iwata, Hiroji
    Tamura, Kenji
    Tsurutani, Junji
    Moreno-Aspitia, Alvaro
    Doi, Toshihiko
    Sagara, Yasuaki
    Redfern, Charles
    Krop, Ian E.
    Lee, Caleb
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Zhang, Lin
    Shahidi, Javad
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (17) : 1887 - +
  • [30] Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
    Strosberg, Jonathan
    Mizuno, Nobumasa
    Doi, Toshihiko
    Grande, Enrique
    Delord, Jean-Pierre
    Shapira-Frommer, Ronnie
    Bergsland, Emily
    Shah, Manisha
    Fakih, Marwan
    Takahashi, Shunji
    Piha-Paul, Sarina A.
    O'Neil, Bert
    Thomas, Sajeve
    Lolkema, Martijn P.
    Chen, Menghui
    Ibrahim, Nageatte
    Norwood, Kevin
    Hadoux, Julien
    CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2124 - 2130
12345